The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Diabetic cardiomyopathy: where we are and where we are going
Open accessAbstract
The global burden of diabetes mellitus and its related complications are currently increasing. Diabetes mellitus affects the heart through various mechanisms including microvascular impairment, metabolic disturbance, subcellular component abnormalities, cardiac autonomic dysfunction, and a maladaptive immune response. Eventually, diabetes mellitus can cause functional and structural changes in the myocardium without coronary artery disease, a disorder known as diabetic cardiomyopathy (DCM). There are many diagnostic tools and management options for DCM, although it is difficult to detect its development and effectively prevent its progression. In this review, we summarize the current research regarding the pathophysiology and pathogenesis of DCM. Moreover, we discuss emerging diagnostic evaluation methods and treatment strategies for DCM, which may help our understanding of its underlying mechanisms and facilitate the identification of possible new therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277 · cited 1×
“The main metabolic abnormalities in diabetes mellitus are hyperglycemia, inflammation, and hyperlipidemia, all of which induce the production of the nitrogen species or reactive oxygen species (ROS) that cause most diabetic complications, including DCM and diabetic nephropathy [18].”
BackgroundDiabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Myocardial Cell Death in Human Diabetes
Frustaci, A., Kajstura, J., Chimenti, C., Jakoniuk, I., Leri, A., Maseri, A., Nadal-Ginard, B., & Anversa, P. (2000) · Circulation Research · doi:10.1161/01.res.87.12.1123 · Cited by 796 · cited 1×
“4-fold higher in the myocardial cells of diabetic patients compared with non-diabetics [55].”
BackgroundCardiac Steatosis in Diabetes Mellitus: A 1 H-Magnetic Resonance Spectroscopy Study
McGavock, J. M., Lingvay, I., Zib, I., Tillery, T., Salas, N., Unger, R., Levine, B. D., Raskin, P., Victor, R. G., & Szczepaniak, L. S. (2007) · Circulation · doi:10.1161/circulationaha.106.645614 · Cited by 612 · cited 2×
“Recently, cardiac steatosis was proposed as an important cause of DCM [41,42].”
BackgroundRijzewijk, L. J., van der Meer, R. W., Smit, J. W. A., Diamant, M., Bax, J. J., Hammer, S., Romijn, J. A., de Roos, A., & Lamb, H. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.062 · Cited by 559 · cited 3×
“Recently, cardiac steatosis was proposed as an important cause of DCM [41,42].”
BackgroundThe pathophysiology of hypertension in patients with obesity
DeMarco, V. G., Aroor, A. R., & Sowers, J. R. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.44 · Cited by 545 · cited 2×
“Moreover, the enhanced activation of mineralocorticoid receptor signaling and AGT II might facilitate insulin resistance by activating the mammalian target of rapamycin-S6 kinase 1 signal transduction pathway [56].”
BackgroundShindler, D. M., Kostis, J. B., Yusuf, S., Quinones, M. A., Pitt, B., Stewart, D., Pinkett, T., Ghali, J. K., Wilson, A. C., & The SOLVD Investigators (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89163-1 · Cited by 516
Xie, Z., Lau, K., Eby, B., Lozano, P., He, C., Pennington, B., Li, H., Rathi, S., Dong, Y., Tian, R., et al. (2011) · Diabetes · doi:10.2337/db10-0351 · Cited by 490 · cited 1×
“Metformin upregulates cardiac autophagy, which plays a role in the prevention of DCM in animal models [94].”
BackgroundThe Effect of Coenzyme Q 10 on Morbidity and Mortality in Chronic Heart Failure
Mortensen, S. A., Rosenfeldt, F., Kumar, A., Dolliner, P., Filipiak, K. J., Pella, D., Alehagen, U., Steurer, G., & Littarru, G. P. (2014) · JACC: Heart Failure · doi:10.1016/j.jchf.2014.06.008 · Cited by 488 · cited 1×
“A randomized controlled trial showed that long-term coenzyme Q10 treatment in patients with chronic heart failure is safe, improves symptoms, and reduces all-cause mortality by 42% and cardiovascular death by 43% [133].”
BackgroundDiabetic Cardiomyopathy: Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options
Aneja, A., Tang, W. H. W., Bansilal, S., Garcia, M. J., & Farkouh, M. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.03.046 · Cited by 482 · cited 14×
“The management of heart failure depends on the severity, type (diastolic or systolic), and associated conditions like CAD and hypertension [1].”
BackgroundInfluentialDiabetic cardiomyopathy: pathophysiology and clinical features
Miki, T., Yuda, S., Kouzu, H., & Miura, T. (2013) · Heart Failure Reviews · doi:10.1007/s10741-012-9313-3 · Cited by 460
Kodama, S., Tanaka, S., Heianza, Y., Fujihara, K., Horikawa, C., Shimano, H., Saito, K., Yamada, N., Ohashi, Y., & Sone, H. (2013) · Diabetes Care · doi:10.2337/dc12-0783 · Cited by 212
RYDEN, L. (2000) · European Heart Journal · doi:10.1053/euhj.2000.2311 · Cited by 174
Younce, C. W., Burmeister, M. A., & Ayala, J. E. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00248.2012 · Cited by 134
Zhou, X., Ma, L., Habibi, J., Whaley-Connell, A., Hayden, M. R., Tilmon, R. D., Brown, A. N., Kim, J.-A., DeMarco, V. G., & Sowers, J. R. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.145136 · Cited by 116 · cited 1×
“This defect is caused by reduced levels of bioavailable nitric oxide [27].”
BackgroundSelf-citationDiabetic cardiomyopathy and metabolic remodeling of the heart
Battiprolu, P. K., Lopez-Crisosto, C., Wang, Z. V., Nemchenko, A., Lavandero, S., & Hill, J. A. (2013) · Life Sciences · doi:10.1016/j.lfs.2012.10.011 · Cited by 91 · cited 2×
“The reciprocal positioning of CD36 and GLUT4 influences the genesis of cardiac metabolic abnormalities that are characterized by metabolic inflexibility [39].”
BackgroundMyocardial collagen turnover in normotensive obese patients: relation to insulin resistance
Quilliot, D., Alla, F., Böhme, P., Bruntz, J.-F., Hammadi, M., Dousset, B., Ziegler, O., & Zannad, F. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0803022 · Cited by 61 · cited 1×
“Serum aminoterminal propeptide of type III, an indicator of type III collagen turnover in the body, was proposed as an early index of LV dysfunction in obese subjects with insulin resistance [82].”
Background
Cited by
Nakamura, K., Miyoshi, T., Yoshida, M., Akagi, S., Saito, Y., Ejiri, K., Matsuo, N., Ichikawa, K., Iwasaki, K., Naito, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073587 · Cited by 268
Mechanism of Ferroptosis and Its Role in Type 2 Diabetes Mellitus
Sha, W., Hu, F., Xi, Y., Chu, Y., & Bu, S. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9999612 · Cited by 266
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms
Salvatore, T., Pafundi, P. C., Galiero, R., Albanese, G., Di Martino, A., Caturano, A., Vetrano, E., Rinaldi, L., & Sasso, F. C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.695792 · Cited by 165
Metadata
- Authors
- Lee, W.-S., & Kim, J.
- Venue
- The Korean Journal of Internal Medicine
- Published
- 2017-05-01
- Volume
- 32
- Issue
- 3
- Pages
- 404-421
- ISSN
- 1226-3303 (ISSN-L)
- 2005-6648
- OpenAlex
- W2606577905
- Cited by
- 163
- References
- 19
- FWCI
- 11.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.